University of Tokyo's TECHNO Breakthrough: Simplified Humanized Mice Model Intractable Diseases

A groundbreaking advancement from the University of Tokyo has revolutionized the creation of humanized mice, offering new hope for studying and treating some of Japan's most challenging health conditions. Researchers at the Institute of Medical Science developed TECHNO, a simplified two-step genome editing method that allows for the precise replacement of large mouse gene regions with their full human counterparts. This innovation, highlighted in a March 19 press release by the Japan Science and Technology Agency (JST), enables the reproduction of characteristics from designated intractable diseases—those rare, chronic conditions with unknown causes or cures that affect millions in Japan.

Humanized mice, which carry human genes in a mouse background, have long been vital tools in biomedical research. Traditional methods struggled with integrating large genomic fragments—often over 100 kilobase pairs (kbp)—including regulatory regions essential for accurate human-like expression. TECHNO overcomes these hurdles using CRISPR-Cas9 technology on mouse embryonic stem (ES) cells, paving the way for more reliable disease models and accelerating drug discovery at Japanese institutions like the University of Tokyo.

Understanding Humanized Mice and Their Role in Research

Humanized mice bridge the gap between basic animal models and human biology by incorporating human genetic material. While mice share about 99% of genes with humans, differences in sequence, especially in non-coding regions, often lead to inaccurate modeling of human diseases. Full-length gene humanization—replacing entire mouse loci with human versions, untranslated regions (UTRs), and promoters—ensures organ- and cell-specific expression patterns mirror those in people.

In Japan, where research on intractable diseases (nanbyō) receives substantial government support, such models are crucial. The Ministry of Health, Labour and Welfare designates 341 conditions as intractable, impacting an estimated 3.5 million patients nationwide. These include genetic disorders like chronic granulomatous disease (CGD), with an incidence of roughly 1 in 250,000 births. Prior mouse models failed to fully recapitulate human pathology, limiting progress in therapies.

The TECHNO Method: A Step-by-Step Breakthrough

TECHNO, short for Two-step ES Cell-based HumaNizatiOn, leverages the high homologous recombination efficiency of mouse ES cells. Here's how it works:

• Step 1: Locus Preparation CRISPR-Cas9 ribonucleoproteins (RNPs) excise the target mouse gene while simultaneously inserting short homology arms (1-3 kbp) flanking a neomycin resistance cassette. This creates a 'scaffold' for the next step, achieving 60-80% efficiency.
• Step 2: Human Gene Insertion A bacterial artificial chromosome (BAC) carrying the full human gene plus a blasticidin resistance cassette is introduced. The pre-inserted arms guide precise integration, yielding 10-15% efficiency even for regions over 200 kbp.

Chimeric mice are generated via blastocyst injection, and germline transmission ensures stable lines. This process, detailed in the January 2026 Nature Communications paper, is versatile across mouse strains like C57BL/6 and BALB/c.

Proof-of-Concept: Successful Humanization of Complex Genes

The team first humanized the c-KIT locus (~100 kbp), critical for hematopoiesis and melanogenesis. Human c-KIT mice showed splicing of all 21 exons in spermatogonia and tissue-specific expression akin to humans—high in cerebellum, lung, and kidney. Functional tests confirmed partial rescue of phenotypes in c-Kit knockouts, including survival and limited spermatogenesis, though some anemia persisted due to ligand incompatibility.

More impressively, they tackled the APOBEC3 cluster (>205 kbp, seven genes), vital for antiviral defense. Lung expression correlated strongly with human patterns, demonstrating TECHNO's scalability for multi-gene families.

Modeling Chronic Granulomatous Disease: A Japanese Priority

CGD, a prime example of Japan's designated intractable diseases, impairs phagocyte reactive oxygen species (ROS) production, leading to recurrent infections. The researchers humanized CYBB (~55 kbp, encoding gp91phox) and introduced patient mutations (T458G, A461Δ). Mutant granulocytes exhibited drastically reduced ROS upon stimulation, mirroring human CGD pathology—viable mice but defective immunity.

This model validates TECHNO for genetic disorders, where single-nucleotide changes cause disease. With CGD affecting dozens annually in Japan, such tools could screen gene therapies or antimicrobials more reliably than cell-based assays.

Advantages Over Traditional Humanization Techniques

• Efficiency: >50-fold better than prior homologous recombination or BAC transgenics for large loci.
• Versatility: Works for ~93% of human genes (<200 kbp); single-copy integration verified by FISH.
• Precision: Retains human regulatory elements, avoiding artifacts from random insertion or partial humanization.
• Speed and Cost: Uses off-the-shelf BACs and standard CRISPR; applicable across strains without custom vectors.

Lead researcher Jumpei Taguchi notes, "TECHNO dramatically improves the feasibility of full-length humanization, opening doors to next-generation models."

University of Tokyo's Leadership in Genome Editing

The Institute of Medical Science (IMS) at UTokyo has pioneered animal model development, supported by JST's Moonshot program and AMED funding for intractable diseases. This TECHNO work builds on IMS expertise in ES cells and CRISPR, positioning UTokyo as a hub for translational biomedicine. Collaborators from Kumamoto University and Osaka University highlight Japan's collaborative research ecosystem.

UTokyo's efforts align with national priorities: Japan's ~¥100 billion annual nanbyō investment funds model development to address 3.5 million patients.

Implications for Drug Development and Intractable Diseases

TECHNO mice promise better preclinical testing. For CGD, they could evaluate novel enzyme replacements or gene therapies ex vivo impossible in standard models. Broader applications include oncology (human KIT signaling), virology (APOBEC3 antiviral roles), and polygenic diseases via multi-locus edits.

In Japan, where 20% of healthcare costs tie to rare diseases, these models could reduce clinical trial failures (currently 90% for first-in-human). For more, see the full study: Nature Communications paper.

Challenges and Ethical Considerations in Humanized Models

Despite advances, challenges remain: potential off-target effects, incomplete functional complementation (e.g., species-specific ligands), and ethical oversight for chimeric models. Japan Agency for Medical Research and Development (AMED) guidelines ensure welfare. TECHNO minimizes disruptions by precise replacement, but validation via RNA-seq and phenotyping is essential.

Future Directions: Scaling TECHNO for Japanese Research

Ozawa's team plans multi-gene humanization for complex pathways and livestock applications. With JST support, UTokyo aims to distribute TECHNO lines via repositories, boosting Japan's biotech sector. Potential for CRISPR prime editing integration could enable rapid mutation libraries for drug screening.

This positions Japanese universities at the forefront of precision medicine, fostering careers in genome engineering. Explore opportunities at research positions.

Broader Impact on Global and Japanese Biomedical Landscape

TECHNO elevates UTokyo's global ranking in life sciences, attracting international collaborators. For Japan, facing aging demographics and rising rare disease burdens, it accelerates therapies, potentially saving billions in healthcare. Students and postdocs at IMS gain hands-on expertise in cutting-edge editing, preparing for biotech leadership.

Photo by Tsuyoshi Kozu on Unsplash